Skip to content

EBITDA at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
Stryker logo
StrykerSYK
Medtronic logo
MedtronicMDT
Boston Scientific logo
Boston ScientificBSX

Other financials

Income statement

See full
Revenue$374.8M+15.6%
Gross profit$253.4M+17.4%
Operating income$38.2M-5.2%
Net income$32.6M-16.9%
EPS (diluted)$0.82-18.0%

Balance sheet

See full
Cash & equivalents$241.3M-35.8%
Total debt$216.2M-2.0%
Total equity$1.5B+21.5%
Total assets$1.9B+19.2%

Cash flow

See full
Operating cash flow$87.0M+77.6%
CapEx$13.7M+1.5%
Free cash flow$73.3M+106%

Valuation

See full
Market cap$12.48B+25.1%
Enterprise value$12.45B+26.8%
P/E72.9×-163×
P/S8.6×+0.5×

Profitability

See full
Gross margin67.4%+3.7pp
Operating margin12.9%+9.8pp
Net margin11.8%+8.4pp
FCF margin14.6%+2.5pp

Returns & leverage

See full
Return on equity12.7%+9.2pp
Debt / equity0.1×0.0×
Current ratio-0.3×

Where this comes from

Calculated from Penumbra’s reported figures.

$38.2Mebit+
$4.6MDepreciation Depletion & Amortization
=$42.81M

The official record: Penumbra’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Penumbra's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Penumbra's EBITDA?
Penumbra (PEN) reported EBITDA of $42.81M in Q1 2026.
How has Penumbra's EBITDA changed year-over-year?
Penumbra's EBITDA decreased by 5.6% year-over-year, from $45.37M to $42.81M.
What is the long-term trend for Penumbra's EBITDA?
Over 4 years (2021 to 2025), Penumbra's EBITDA has grown at a 119.5% compound annual growth rate (CAGR), from $8.91M to $206.72M.
What does EBITDA mean?
Operating cash profit before interest, taxes, and non-cash charges.
How do you interpret EBITDA?
Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
How does EBITDA compare across companies?
Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.